United Kingdom · Question · Written question
UIN 87
Bicalutamide
Original
Introduced
10 May 2022
Last action
16 May 2022 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
16 May 2022
Summary
To ask the Secretary of State for Health and Social Care, what assessment he has made of the therapeutic benefits of bicalutamide in halting the growth of prostate cancer; and if he will make a statement.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
10 May 2022
Written question
To ask the Secretary of State for Health and Social Care, what assessment he has made of the therapeutic benefits of bicalutamide in halting the growth of prostate cancer; and if he will make a statement.
Source: Commons
16 May 2022
Answer
We have made no specific assessment. However, bicalutamide (casodex) has been licensed in the United Kingdom for the treatment of advanced prostate cancer since 2000. The National Institute for Health and Care Excellence has made recommendations on use of...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2022-05-10/87
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1461553
- uk · wq-1461553 · source updated 16 May 2022